Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
Boehringer Ingelheim announced today that it has acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of allergic skin diseases. “We’re excited to have the potential […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
